The US FDA has launched an investigation into Novartis’ one-time spinal muscular atrophy gene therapy Zolgensma after cancer cases were reported, the agency said. The probe is prompted by what FDA characterized as a serious risk of cancer associated with the therapy. The action follows Novartis’ recent disclosure tied to the safety signal and underscores regulators’ continued scrutiny of long-term risks for gene-transfer products. For biotech companies, the FDA move reinforces that post-marketing surveillance and adverse-event reporting remain central to managing durability and safety for next-generation platforms. While no specific causal mechanism is described in the available briefing, the investigation adds pressure for sponsors and clinicians to align on monitoring strategies for malignancy outcomes in treated pediatric populations. It also increases the probability of additional label, registry, or follow-up study requirements as data are gathered. Zolgensma’s wide adoption makes the FDA step particularly consequential for the gene therapy sector—both for market access planning and for expectations around risk communication.